WHO pushes for removal of mercury from medical devices; Boston Scientific gears up for Q3 results;

@FierceMedDev: CardioKinetix heart failure treatment device reaches China. More | Follow @FierceMedDev

@MarkHFierce: St. Jude Medical snatches up a company and gets a leadless pacemaker (and possible market edge) in the process. Release | Follow @MarkHFierce

@MichaelGFierce: Gov't shutdown halts FCC's wireless med tech certification. ICYMI Friday | Follow @MichaelGFierce

> Novartis ($NVS) is slashing jobs at its vaccine and diagnostic operation in Emeryville, CA, in order to focus more on diagnostics. Item

> The World Health Organization (WHO) and Health Care Without Harm are pushing for the removal of mercury from all medical devices (such as thermometers and blood pressure measuring gauges) by 2020. Story

> Surgical device company Misonix said it has ended a license and distribution agreement with PuriCore. Item

> A high-tech implant designed to encourage cells damaged by Parkinson's disease to grow again is showing promise. Story

> A team of researchers in Toronto has developed a robotic suturing tool designed for laparoscopic surgery. Story

> Boston Scientific ($BSX) plans to discuss its 2013 third quarter financial results on Thursday, Oct. 24. Item

Biotech News

@FierceBiotech: Parexel looks to Japan for growth. Story from FierceCRO | Follow @FierceBiotech

@JohnCFierce: Merck KGaA scouts for deep-pocketed partners to leverage its R&D budget. Article | Follow @JohnCFierce

@DamianFierce: While "porcine whipworm" rolls off the tongue, it doesn't seem to do much for Crohn's. Story | Follow @DamianFierce

> In a big shift, analyst takes a skeptical stance on Merck's R&D prospects. Story

> Eli Lilly gambling up to $86M on China cancer drug development deal. News

> Vital Therapies plots $86M IPO as biotech market boils. Report

Pharma News

@FiercePharma: ICYMI: Top 10 Drugmakers in Emerging Markets. Special report | Follow @FiercePharma

@EricPFierce: Big forecasts for biologics like Kadclya, lead Roche to invest $900 million in biologics production. Article | Follow @EricPFierce

@CarlyHFierce: FiercePharma gets a shoutout in The New York Times (as a source for this asthma piece).  | Follow @CarlyHFierce

> Sanofi nabs OTC nod for Nasacort amid consumer healthcare push. More

> Roche to supersize biologics production to meet biologics' super forecasts. Story

> Irate Teva reps vow to strike against Israeli job cuts. Report

> FDA staff report puts hurt on Amarin. Report

CRO News

> Quintiles snags registry deal with Muscular Dystrophy Association. Report

> U.K. CRO Cmed expands its U.S. foothold. Item

> Yale partners up to run medical device trials. More

> Icon deepens adaptive trial work with patient-safety service. Story

> Catalent buys up Brazilian CMO with eye on growing market. Article

Biotech IT News

> EDC tops poll of R&D productivity technologies. Article

> From Hollywood to healthcare: How 3-D modeling is shaping drug development. More

> Sanger Institute taps DDN to help with Big Data boom. Article

> Venter outlines plan to print vaccines on Mars. Item

> New details on brains and budget behind Google's Calico emerge. Story

Suggested Articles

J&J launched a virtual clinical study to gauge whether Apple’s iPhone and ECG-enabled smartwatch can help reduce the risk of stroke and catch AFib.

The Salt Lake City-based developer said its Logix Smart test is now available to be exported from Utah to countries requiring the CE Mark.

Dexcom received a new European approval for its wearable continuous glucose monitor in pregnant women across Type 1, Type 2 and gestational diabetes.